PRTCY
PureTech Health plc
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
15.79
▲ 0.29 (1.87%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
15.79
Prev close
15.50
Day high
15.79
Day low
15.79
Volume
373
Market cap
$384.36M
P/E (TTM)
—
52W range
14.50 – 19.92
Day trading desk
Gap from prior close
+1.87%
Prior close 15.50
VWAP
15.79
+0.00% from price
Relative volume
0.07×
Quiet session
Session range
0.00%
15.79 – 15.79
Position in range
100%
Near session high
ATR (14D)
0.29
1.81% of price
Prior day high
15.94
PDH
Prior day low
15.50
PDL
Bid / ask spread
—
Quote not published
Session volume
100
Avg 1.53K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.31%
+0.1%
1M
-5.45%
-9.2%
3M
-9.25%
-12.3%
6M
-10.34%
-21.4%
YTD
-5.11%
-17.4%
1Y
-14.00%
-34.0%
3Y
-37.86%
-112.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PRTCY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$384.36M
Enterprise value$292.50M
Revenue (TTM)$4.66M
Gross profit$-51.80M
EBITDA$-96.83M
Net income$-109.74M
EPS (TTM)$-4.60
Free cash flow$-89.99M
Total cash$288.72M
Total debt$203.26M
Book value / share$12.91
Shares outstanding24.34M
Float15.68M
Short % of float0.12%
Dividend yield—
Beta (5Y)0.77
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book1.22
EV / revenue62.78
EV / EBITDA-3.02
Gross margin0.00%
Operating margin-1797.79%
Profit margin0.00%
Return on equity-30.85%
Return on assets-10.82%
Debt / equity66.49
Current ratio6.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.66M | $4.32M | $750.00K | $2.09M | +8.0% |
| Operating revenue | $4.66M | $4.32M | $750.00K | $2.09M | +8.0% |
| Research & development | $45.74M | $54.28M | $73.73M | $111.29M | -15.7% |
| Selling, general & admin | $20.65M | $27.49M | $25.18M | $31.60M | -24.9% |
| Total operating expense | $103.18M | $140.41M | $146.95M | $199.90M | -26.5% |
| Operating income | -$98.53M | -$136.09M | -$146.20M | -$197.81M | +27.6% |
| Net interest income | -$32.73M | $12.63M | $2.52M | $1.85M | -359.1% |
| Pre-tax income | -$110.93M | $23.77M | -$36.10M | -$92.78M | -566.6% |
| Tax provision | -$842.00K | -$4.01M | $30.52M | -$55.72M | +79.0% |
| Net income | -$109.74M | $53.51M | -$65.70M | -$50.35M | -305.1% |
| Net income to common | -$109.74M | $53.51M | -$65.70M | -$50.35M | -305.1% |
| Basic EPS | -4.60 | 2.10 | -2.40 | -1.80 | -319.0% |
| Diluted EPS | -4.60 | 2.10 | -2.40 | -1.80 | -319.0% |
| EBIT | -$65.15M | $33.81M | -$22.61M | -$88.83M | -292.7% |
| EBITDA | -$61.80M | $37.38M | -$17.68M | -$79.94M | -265.3% |
| Basic shares | 24.08M | 25.45M | 27.63M | 28.48M | -5.4% |
| Diluted shares | 24.08M | 25.60M | 27.63M | 28.48M | -6.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $252.47M | $280.64M | $191.08M | $149.87M | — | -10.0% |
| Cash & short-term investments | $277.30M | $367.31M | $327.14M | $350.10M | — | -24.5% |
| Accounts receivable | $1.76M | $1.52M | $2.38M | $11.87M | — | +15.5% |
| Total current assets | $305.02M | $386.26M | $347.20M | $386.19M | — | -21.0% |
| Property, plant & equipment | $11.50M | $15.13M | $19.36M | $37.24M | — | -24.0% |
| Goodwill & intangibles | $601.00K | $601.00K | $906.00K | $831.00K | — | 0.0% |
| Total assets | $534.71M | $602.63M | $693.97M | $702.65M | — | -11.3% |
| Total current liabilities | $46.31M | $41.39M | $51.37M | $96.89M | — | +11.9% |
| Current debt | $4.92M | $4.11M | $3.70M | $7.50M | — | +19.6% |
| Long-term debt | — | — | $0 | $10.24M | $14.26M | — |
| Total debt | $19.59M | $22.36M | $25.34M | $46.87M | — | -12.4% |
| Total liabilities | $229.03M | $194.70M | $235.74M | $155.06M | — | +17.6% |
| Retained earnings | -$77.23M | $32.49M | $83.82M | $149.52M | — | -337.7% |
| Shareholder equity | $312.07M | $414.71M | $464.07M | $542.22M | — | -24.7% |
| Working capital | $258.71M | $344.87M | $295.83M | $289.31M | — | -25.0% |
| Net tangible assets | $311.47M | $414.11M | $463.16M | $541.39M | — | -24.8% |
| Shares issued | 257.93M | 257.93M | 289.47M | 289.16M | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$110.08M | $27.78M | -$66.63M | -$37.06M | -496.2% |
| Depreciation & amortisation | $3.35M | $3.57M | $4.93M | $8.89M | -6.2% |
| Stock-based compensation | $8.22M | $22.85M | $4.42M | $14.70M | -64.0% |
| Change in working capital | -$3.12M | -$10.24M | $17.52M | $15.92M | +69.5% |
| Operating cash flow | -$85.13M | -$134.37M | -$105.92M | -$178.79M | +36.6% |
| Capital expenditure | -$6.00K | -$11.00K | -$245.00K | -$2.18M | +45.5% |
| Investing cash flow | $63.29M | $240.89M | $68.99M | -$107.22M | -73.7% |
| Share buybacks | -$2.05M | -$107.56M | -$19.65M | -$26.49M | +98.1% |
| Financing cash flow | -$6.33M | -$16.96M | $78.14M | -$29.83M | +62.7% |
| Free cash flow | -$85.14M | -$134.38M | -$106.16M | -$180.97M | +36.6% |
| End cash position | $252.47M | $280.64M | $191.08M | $149.87M | -10.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $252.47M | $260.60M | $280.64M | -3.1% |
| Cash & short-term investments | $277.30M | $321.55M | $367.31M | -13.8% |
| Accounts receivable | $1.76M | $2.49M | $1.52M | -29.3% |
| Total current assets | $305.02M | $344.39M | $386.26M | -11.4% |
| Property, plant & equipment | $11.50M | $13.31M | $15.13M | -13.6% |
| Goodwill & intangibles | $601.00K | $601.00K | $601.00K | 0.0% |
| Total assets | $534.71M | $553.24M | $602.63M | -3.3% |
| Total current liabilities | $46.31M | $40.58M | $41.39M | +14.1% |
| Current debt | $4.92M | $4.50M | $4.11M | +9.3% |
| Total debt | $19.59M | $20.92M | $22.36M | -6.4% |
| Total liabilities | $229.03M | $184.22M | $194.70M | +24.3% |
| Retained earnings | -$77.23M | -$12.10M | $32.49M | -538.4% |
| Shareholder equity | $312.07M | $375.98M | $414.71M | -17.0% |
| Working capital | $258.71M | $303.81M | $344.87M | -14.8% |
| Net tangible assets | $311.47M | $375.37M | $414.11M | -17.0% |
| Shares issued | 257.93M | 257.93M | 257.93M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $7.10M | +52.4% |
| Next year | — | — | $13.47M | +89.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.00%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.93
-0.90% from price
SMA 20
15.92
-0.79% from price
SMA 50
16.60
-4.90% from price
SMA 100
16.91
-6.64% from price
SMA 200
17.02
-7.25% from price
EMA 12
15.91
-0.77% from price
EMA 26
16.13
-2.12% from price
EMA 50
16.43
-3.92% from price
RSI (14)
44.7
Neutral
MACD (12,26,9)
-0.22
Hist 0.02
ATR (14)
0.29
1.81% of price
Realised vol 30D
35.2%
Annualised
Bollinger upper
16.56
20, 2σ
Bollinger lower
15.27
20, 2σ
50 / 200 cross
Death
16.60 vs 17.02
Trend bias
Below 200
-7.25%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.57
Less volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
35.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-26.1%
Peak to trough
Max drawdown 5Y
-74.7%
Peak to trough
ATR 14
0.29
1.81% of price
Beta (reported)
0.77
5Y monthly, from filing
Short interest
Shares short
24.52K
Prior 14.82K
Change vs prior
+65.4%
Shorts adding
% of float
0.12%
Normal
% of shares out
0.10%
Against total outstanding
Days to cover
3.9
Liquid
Float
15.68M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Headlines
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · 41d ago
Celea Therapeutics secures $180m for Phase III SURPASS-IPF trial
Clinical Trials Arena · 51d ago
A PureTech startup banks $180M for a new IPF drug
BioPharma Dive · 52d ago
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · 52d ago
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · 52d ago
PureTech Health: Results of Annual General Meeting
Business Wire · 74d ago
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Business Wire · 75d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.